Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Capital Expenditures (2021 - 2026)

Neuroone Medical Technologies filings provide 6 years of Capital Expenditures readings, the most recent being $38516.0 for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 1114.63% to $38516.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $133425.0, a 68.27% increase, with the full-year FY2025 number at $81742.0, down 31.99% from a year prior.
  • Capital Expenditures hit $38516.0 in Q1 2026 for Neuroone Medical Technologies, down from $40754.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $175694.0 in Q1 2023 to a low of $3171.0 in Q1 2025.
  • Median Capital Expenditures over the past 5 years was $38516.0 (2026), compared with a mean of $51709.5.
  • Biggest five-year swings in Capital Expenditures: plummeted 89.89% in 2025 and later soared 1114.63% in 2026.
  • Neuroone Medical Technologies' Capital Expenditures stood at $11512.0 in 2022, then surged by 222.54% to $37131.0 in 2023, then tumbled by 34.24% to $24416.0 in 2024, then surged by 66.92% to $40754.0 in 2025, then dropped by 5.49% to $38516.0 in 2026.
  • The last three reported values for Capital Expenditures were $38516.0 (Q1 2026), $40754.0 (Q4 2025), and $10607.0 (Q3 2025) per Business Quant data.